Located in Shenzhen, China, Cheerland Biotechnology strives to become a world leader in biologics CDMO. We provide first-class, large-scale biologics CDMO services to international biotech companies. Our clients can rely upon the most advanced equipment and process design, a world-class management team, and services tailored to client needs. Led by Michael Garvey, we have built a global management team with industry veterans from Lonza, Samsung Biologics, Roche, Novartis, and other pharma giants. Together they brought to Cheerland a wealth of expertise and experiences in R&D, GMP manufacturing, and global regulatory affairs and quality control. Working with our global partners, including Alfa Laval, Cytiva, Sartorius, Thermo Fisher, Siemens, and IBM, we are also building the first AI-Supported Smart Bio-Factory in Asia. Based on Digital 4.0 principles, we are combining the power of IoT, augmented data analytics, and autonomous manufacturing systems, to revolutionize biologics CDMO services. Our clients also enjoy the Cheerland Advantages in scale, cost reduction and market competitiveness. Cheerland Shenzhen Biologics I will be completed in 2022, and Shenzhen II in 2025; by then our full capacity will surpass 1 million liters, becoming the world’s largest biologics CDMO service provider. Cheerland is the first in China to utilize the 15kL bioreactor, driving production cost down significantly. In addition, Cheerland provides a unique advantage in finance and platform support. We are working with leading institution investors to establish VC funds of up to 10Bn RMB in total size, focusing on biomedicine projects. We also share extensive resources on the Cheerland platform, helping our clients to achieve market success in commercialization. Cheerland Biotechnology looks forward to working with you, for better biomedicine, and a healthier world. Cheerland Biotechnology, the world's local CDMO.